AR052889A1 - Anticuerpos contra interleuquina-1 beta - Google Patents

Anticuerpos contra interleuquina-1 beta

Info

Publication number
AR052889A1
AR052889A1 ARP060100271A ARP060100271A AR052889A1 AR 052889 A1 AR052889 A1 AR 052889A1 AR P060100271 A ARP060100271 A AR P060100271A AR P060100271 A ARP060100271 A AR P060100271A AR 052889 A1 AR052889 A1 AR 052889A1
Authority
AR
Argentina
Prior art keywords
sequences
interleuquine
beta
1beta
antigen
Prior art date
Application number
ARP060100271A
Other languages
English (en)
Inventor
Larry L Green
Raffaella Faggioni
Orit Foord
Scott L Klakamp
Giorgio Senaldi
Amy K Schneider
Original Assignee
Abgenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abgenix Inc filed Critical Abgenix Inc
Publication of AR052889A1 publication Critical patent/AR052889A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/801—Drug, bio-affecting and body treating compositions involving antibody or fragment thereof produced by recombinant dna technology
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Anticuerpos dirigidos contra el antígeno IL-1beta, y usos para dichos anticuerpos. En particular, se describen anticuerpos monoclonales completamente humanos dirigidos contra el antígeno IL-1beta. Se describen secuencias de nucleotidos codificantes, y secuencias de aminoácidos que comprenden moléculas de las cadenas pesada y liviana de la inmunoglobulina, particularmente secuencias que corresponden a secuencias contiguas de las cadena pesada y liviana, que comprenden las regiones marco y/o las regiones de determinacion de la complementariedad (CDR), específicamente de FR1 a FR4 o CDR1 a CDR3. Se describen hibridomas u otras líneas celulares que experesan estas moléculas de inmunoglobulina y anticuerpos monoclonales.
ARP060100271A 2005-01-26 2006-01-25 Anticuerpos contra interleuquina-1 beta AR052889A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64764305P 2005-01-26 2005-01-26
US75380005P 2005-12-22 2005-12-22

Publications (1)

Publication Number Publication Date
AR052889A1 true AR052889A1 (es) 2007-04-11

Family

ID=36740960

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100271A AR052889A1 (es) 2005-01-26 2006-01-25 Anticuerpos contra interleuquina-1 beta

Country Status (8)

Country Link
US (2) US7566772B2 (es)
EP (2) EP1851245B1 (es)
AR (1) AR052889A1 (es)
AU (1) AU2006208286A1 (es)
CA (1) CA2590164A1 (es)
ES (1) ES2395953T3 (es)
TW (1) TW200637873A (es)
WO (1) WO2006081139A2 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0411852A (pt) 2003-06-27 2006-05-23 Abgenix Inc anticorpos dirigidos aos mutantes de deleção de receptor de fator de crescimento epidérmico e seu usos
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
PT2314623E (pt) 2005-06-21 2012-10-02 Xoma Technology Ltd Anticorpos de ligação a il-1β e os seus fragmentos
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
CL2007002668A1 (es) 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
RU2554747C9 (ru) 2006-12-20 2015-10-20 Ксома (Сша) Ллс Способы лечения il-1бета-зависимых заболеваний
EP3406263A1 (en) 2007-05-29 2018-11-28 Novartis AG New indications for anti-il-1beta therapy
WO2009067800A1 (en) 2007-11-27 2009-06-04 Viventia Biotech Inc. Antibodies against a cancer-associated epitope of variant nfkbib and uses thereof
PT2391650E (pt) 2007-12-20 2015-01-14 Xoma Us Llc Métodos para o tratamento de gota
SG190572A1 (en) * 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
RU2010153578A (ru) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойными вариабельными доменами и их применение
CA2726087A1 (en) 2008-06-03 2009-12-10 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
RU2011104348A (ru) 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
US8377429B2 (en) 2008-09-05 2013-02-19 Xoma Technology Ltd. Methods for improvement of beta cell function with anti-IL-1β antibodies or fragments thereof
WO2010138939A1 (en) 2009-05-29 2010-12-02 Xoma Technology Ltd. CARDIOVASCULAR RELATED USES OF IL-1ß ANTIBODIES AND BINDING FRAGMENTS THEREOF
KR20120060877A (ko) * 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US9885711B2 (en) 2009-09-25 2018-02-06 Xoma Technology Ltd. Screening methods
AU2010306677B2 (en) * 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
SG10201502587SA (en) 2010-03-01 2015-06-29 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
US8551487B2 (en) * 2010-05-07 2013-10-08 Xoma Technology, Ltd. Methods for the treatment of IL-1β related conditions
KR20130100118A (ko) * 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
EP2614085B1 (en) * 2010-09-10 2016-04-20 Apexigen, Inc. Anti-il-1 beta antibodies and methods of use
US20150017157A1 (en) 2011-12-19 2015-01-15 Xoma (Us) Llc Methods for treating acne
TW201333035A (zh) 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
EP2814843B1 (en) * 2012-02-13 2020-03-18 Agency For Science, Technology And Research IL-ß NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
CA2890263C (en) 2012-11-01 2020-03-10 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
US9404930B2 (en) * 2012-11-05 2016-08-02 Delenex Therapeutics Ag Antibody to human IL-1 beta
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
ES2895848T3 (es) 2012-12-17 2022-02-22 Cell Medica Inc Anticuerpos contra IL-1 beta
MX2015009901A (es) 2013-02-01 2016-04-06 Santa Maria Biotherapeutics Inc Administración de un compuesto de antiactivina a a un sujeto.
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
EP3712166A1 (en) 2013-09-05 2020-09-23 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
PT3126391T (pt) 2014-03-31 2019-11-27 Univ Hospital Of North Norway Anticorpos contra hpa-1a
WO2015175861A1 (en) 2014-05-16 2015-11-19 Amgen Inc. Assay for detecting th1 and th2 cell populations
CA3005158A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
EP3307779A2 (en) * 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
ES2944982T3 (es) 2015-08-05 2023-06-27 Janssen Biotech Inc Anticuerpos anti-CD154 y métodos para utilizarlos
LT3350220T (lt) 2015-09-15 2021-09-27 Scholar Rock, Inc. Anti pro/latentinio miostatino antikūnai ir jų panaudojimas
CN109069622A (zh) * 2015-09-30 2018-12-21 詹森生物科技公司 特异性结合人cd40的拮抗性抗体和使用方法
CN109071645A (zh) 2016-01-08 2018-12-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
KR102271635B1 (ko) 2016-06-13 2021-07-06 스칼러 락, 인크. 미오스타틴 억제제의 용도 및 조합 요법
SG10201606949QA (en) * 2016-08-19 2018-03-28 Singapore Health Serv Pte Ltd Immunosuppressive composition for use in treating immunological disorders
FI3565592T3 (fi) 2017-01-06 2023-05-10 Scholar Rock Inc Metabolisten tautien hoitaminen estämällä myostatiinin aktivaatio
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
CN106928354B (zh) * 2017-04-25 2020-07-17 长春金赛药业有限责任公司 抗IL-1β单克隆抗体及其应用
CN117700548A (zh) 2017-08-03 2024-03-15 艾利妥 抗cd33抗体及其使用方法
MA52186A (fr) 2018-03-26 2021-02-17 Amgen Inc Glycoformes afucosylées totales d'anticorps produits en culture cellulaire
US20220064282A1 (en) * 2018-11-07 2022-03-03 Zeda Biopharmaceuticals, Inc. Antibody binding to human il-1 beta, preparation method therefor and use thereof
KR102087743B1 (ko) * 2019-06-10 2020-03-12 을지대학교 산학협력단 IL-1beta에 특이적으로 결합하는 항체 및 그의 용도
WO2021062372A1 (en) 2019-09-26 2021-04-01 Amgen Inc. Methods of producing antibody compositions
WO2021099944A1 (en) * 2019-11-18 2021-05-27 Janssen Biotech, Inc. Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof
US20210395344A1 (en) * 2020-04-27 2021-12-23 Twist Bioscience Corporation Variant nucleic acid libraries for coronavirus
EP4162257A1 (en) 2020-06-04 2023-04-12 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
EP4229080A1 (en) 2020-10-15 2023-08-23 Amgen Inc. Relative unpaired glycans in antibody production methods
WO2022150809A1 (en) * 2021-01-05 2022-07-14 Immunome, Inc. Antibody cocktail against sars-cov-2 spike protein
EP4352094A1 (en) 2021-06-07 2024-04-17 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
WO2023059607A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
CN114989299B (zh) * 2022-06-21 2023-05-26 北京索莱宝科技有限公司 一种单克隆抗体的组合物及其应用、检测人白细胞介素1β的试剂、试剂盒和方法

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3180193A (en) 1963-02-25 1965-04-27 Benedict David Machines for cutting lengths of strip material
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ATE12348T1 (de) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
JPS58166634A (ja) 1982-03-29 1983-10-01 Toshiba Corp 有機溶媒電池用正極
JPS58166633A (ja) 1982-03-29 1983-10-01 Toshiba Corp 有機溶媒電池用正極
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3486459D1 (de) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
EP0569687B1 (en) 1984-05-18 2002-08-21 New England Medical Center Hospitals, Inc. Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
US5484887A (en) 1984-06-19 1996-01-16 Immunex Corporation Homogeneous interleukin 1
JPS62170639A (ja) 1986-01-22 1987-07-27 株式会社システムメンテナンス 防蟻板の取付け工法
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4935343A (en) 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
DK590387A (da) 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
FR2615622B1 (fr) 1987-05-19 1994-05-06 Ire Medgenix Sa Dosage plasmatique de monokines
KR0148009B1 (ko) 1988-05-27 1998-08-01 그래고리 비. 아보트 인터루킨-1 억제제
JP2554528B2 (ja) 1988-09-19 1996-11-13 大塚製薬株式会社 副腎皮質刺激ホルモン分泌能検査薬
DE68925935T2 (de) 1988-10-01 1996-08-14 Otsuka Pharma Co Ltd Antikörper gegen Interleukin-1-beta
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
FR2640146B1 (fr) 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
DE68927671T2 (de) 1988-12-19 1997-05-07 American Cyanamid Co Produkte zur Behandlung des Endotoxin -Schocks bei einem Säugetier
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
FR2664073A1 (fr) 1990-06-29 1992-01-03 Thomson Csf Moyens de marquage d'objets, procede de realisation et dispositif de lecture.
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
WO1992003917A1 (en) 1990-08-29 1992-03-19 Genpharm International Homologous recombination in mammalian cells
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992010210A1 (en) 1990-12-14 1992-06-25 E.I. Du Pont De Nemours And Company Inhibition of angiogenesis by il-1
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1993000433A1 (en) 1991-06-28 1993-01-07 New England Deaconess Hospital A differentiated megakaryocyte line producing novel megakaryocyte differentiation factors
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
TW318189B (es) 1991-12-06 1997-10-21 American Cyanamid Co
EP0648265A4 (en) 1992-06-18 1996-12-04 Genpharm Int PROCESS FOR THE PRODUCTION OF NON-HUMAN TRANSGENIC ANIMALS HAVING AN ARTIFICIAL YEAST CHROMOSOME.
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5985838A (en) * 1993-04-29 1999-11-16 Vertex Pharmaceuticals, Inc. Peptide analogs as irreversible interleukin-1β protease inhibitors
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5686246A (en) 1995-08-03 1997-11-11 Kornman; Kenneth S. Detecting genetic predisposition to periodontal disease
GB9517538D0 (en) 1995-08-26 1995-10-25 Therapeutic Antibodies Inc Production and therapeutic combinations, of antibodies
AU718138B2 (en) 1995-08-29 2000-04-06 Kyowa Hakko Kirin Co., Ltd. Chimeric animal and method for constructing the same
US6406710B1 (en) 1996-01-16 2002-06-18 Nikos Panayotatos Protein occlusion for delivery of small molecules
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
US6407218B1 (en) 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
EP1068312A2 (en) * 1998-04-09 2001-01-17 Genset 5' ests and encoded human proteins
US6251598B1 (en) 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
AU778975B2 (en) 1999-02-10 2004-12-23 Interleukin Genetics, Inc. Therapeutics and diagnostics based on an IL-1B mutation
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
DE60137421D1 (de) 2000-06-29 2009-03-05 Abbott Lab Antikörper mit zwei spezifizitäten und verfahren zur deren herstellung und verwendung
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US20050075488A1 (en) * 2001-07-26 2005-04-07 Bright Stuart Willis Interleukin-1 beta antibodies
JP2005510253A (ja) 2001-11-30 2005-04-21 アブジェニックス インコーポレイテッド ヒトＩｇλ軽鎖遺伝子を保有するトランスジェニック動物
CN1780855B (zh) * 2003-01-24 2011-03-30 应用分子进化公司 人IL-1β拮抗剂
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
GB0312481D0 (en) * 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
JP6071725B2 (ja) 2013-04-23 2017-02-01 カルソニックカンセイ株式会社 電気自動車の駆動力制御装置
US11284893B2 (en) 2019-04-02 2022-03-29 Covidien Lp Stapling device with articulating tool assembly

Also Published As

Publication number Publication date
US7964193B2 (en) 2011-06-21
US7566772B2 (en) 2009-07-28
EP2361933A2 (en) 2011-08-31
AU2006208286A1 (en) 2006-08-03
WO2006081139A2 (en) 2006-08-03
EP2361933A3 (en) 2012-05-02
EP1851245A4 (en) 2008-05-14
EP1851245B1 (en) 2012-10-10
EP1851245A2 (en) 2007-11-07
WO2006081139A3 (en) 2007-02-15
ES2395953T3 (es) 2013-02-18
TW200637873A (en) 2006-11-01
US20070065439A1 (en) 2007-03-22
US20100183616A1 (en) 2010-07-22
CA2590164A1 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
AR052889A1 (es) Anticuerpos contra interleuquina-1 beta
UY29288A1 (es) Anticuerpos dirigidos contra angiopoyetina-2 y usos de los mismos
UY29573A1 (es) Anticuerpos dirigidos contra cd20 y sus usos
UY30260A1 (es) Anticuerpos dirigidos contra upar y usos de los mismos
AR062213A1 (es) Anticuerpos dirigidos contra (alfa v beta 6) y usos de los mismos
ES2547463T3 (es) Moléculas de unión a ILT3 y usos de las mismas
AR058322A1 (es) Proteinas de union especificas de factores de crecimiento tipo insulina y usos de las mismas
BRPI0511782A (pt) anticorpos anti-cd3 e métodos de uso dos mesmos
ES2570853T3 (es) Moléculas de anticuerpo humanizadas específicas para IL-31
BR0318454A (pt) anticorpos dirigidos a hormÈnio da paratireóide (pth) e seus usos
MXPA05005925A (es) Anticuerpos dirigidos a la fosfolipasa a2 y sus usos.
WO2006039258A3 (en) Human antibodies against parathyroid hormone
LT2005099A (en) Antibodies directed to monoclonal chemo-atractant protein-1 (mcp-1) and uses thereof
WO2007109307A3 (en) Antibodies directed to angiopoietin-like protein 4 and uses thereof
RS54088B1 (en) B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
WO2006052591A3 (en) Anti-properdin antibodies, and methods for making and using same
WO2006104978A3 (en) Antibodies against the tenascin major antigens
AR066913A1 (es) Metodos y composiciones para inducir la apoptosis en celulas cancerosas

Legal Events

Date Code Title Description
FB Suspension of granting procedure